Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,208
  • Shares Outstanding, K 175,405
  • Annual Sales, $ 116,880 K
  • Annual Income, $ -25,090 K
  • 60-Month Beta 0.95
  • Price/Sales 1.62
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RIGL with:

Options Overview Details

View History
  • Implied Volatility 126.32% ( +19.45%)
  • Historical Volatility 52.82%
  • IV Percentile 73%
  • IV Rank 40.13%
  • IV High 307.91% on 01/09/24
  • IV Low 4.61% on 10/02/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 115
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 12,322
  • Open Int (30-Day) 12,370

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 4
  • High Estimate -0.01
  • Low Estimate -0.04
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +13.37%
on 04/19/24
1.5050 -23.92%
on 03/28/24
-0.2750 (-19.37%)
since 03/22/24
3-Month
1.0100 +13.37%
on 04/19/24
1.7300 -33.82%
on 03/06/24
-0.1250 (-9.84%)
since 01/23/24
52-Week
0.7120 +60.81%
on 10/25/23
1.9600 -41.58%
on 05/18/23
-0.0450 (-3.78%)
since 04/21/23

Most Recent Stories

More News
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 1.1400 (+0.88%)
Rigel Announces Presentation at the Upcoming IDWeek 2023

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical...

RIGL : 1.1400 (+0.88%)
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...

RIGL : 1.1400 (+0.88%)
Rigel to Present at the 2023 Cantor Global Healthcare Conference

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...

RIGL : 1.1400 (+0.88%)
Rigel to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean...

RIGL : 1.1400 (+0.88%)
Rigel: Q2 Earnings Snapshot

Rigel: Q2 Earnings Snapshot

RIGL : 1.1400 (+0.88%)
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2023, including sales of...

RIGL : 1.1400 (+0.88%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 1.1400 (+0.88%)
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA®...

RIGL : 1.1400 (+0.88%)
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and...

RIGL : 1.1400 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 1.2400
2nd Resistance Point 1.1900
1st Resistance Point 1.1600
Last Price 1.1400
1st Support Level 1.0800
2nd Support Level 1.0300
3rd Support Level 1.0000

See More

52-Week High 1.9600
Fibonacci 61.8% 1.4833
Fibonacci 50% 1.3360
Fibonacci 38.2% 1.1887
Last Price 1.1400
52-Week Low 0.7120

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar